$PLX
Protalix BioTherapeutics, Inc.

2015 Q2 Form 10-Q Financial Statement

#000114420415028431 Filed on May 07, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q1
Revenue $1.336M $4.392M $6.696M
YoY Change -44.91% -34.41% 87.67%
Cost Of Revenue $225.0K $2.400M $4.073M
YoY Change -85.98% -41.08% 319.46%
Gross Profit $1.111M $2.697M $3.310M
YoY Change 2.78% -18.52% 10.44%
Gross Profit Margin 83.16% 61.41% 49.43%
Selling, General & Admin $2.001M $1.822M $3.711M
YoY Change 27.78% -50.9% 76.46%
% of Gross Profit 180.11% 67.56% 112.11%
Research & Development $6.023M $6.100M $8.152M
YoY Change -14.88% -25.17% 5.13%
% of Gross Profit 542.12% 226.18% 246.28%
Depreciation & Amortization $600.0K $616.0K $828.0K
YoY Change -25.0% -25.6% -10.97%
% of Gross Profit 54.01% 22.84% 25.02%
Operating Expenses $8.024M $7.922M $11.86M
YoY Change -7.15% -33.22% 20.35%
Operating Profit -$5.584M -$5.384M -$6.468M
YoY Change 2.52% -16.76% 46.04%
Interest Expense -$600.0K -$1.130M -$880.0K
YoY Change -10.45% 28.41% -900.0%
% of Operating Profit
Other Income/Expense, Net -$599.0K -$1.129M -$877.0K
YoY Change -10.86% 28.73% -912.04%
Pretax Income -$6.180M -$6.510M -$7.350M
YoY Change 0.98% -11.43% 70.14%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$5.071M -$5.972M -$7.345M
YoY Change -17.13% -18.69% 69.98%
Net Earnings / Revenue -379.57% -135.97% -109.69%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.54 -$0.64 -$0.79
COMMON SHARES
Basic Shares Outstanding 93.60M shares 93.60M shares 93.58M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $43.20M $48.00M $77.70M
YoY Change -39.24% -38.22% 85.44%
Cash & Equivalents $43.24M $47.96M $77.69M
Short-Term Investments
Other Short-Term Assets $2.300M $2.931M $2.600M
YoY Change 15.0% 12.73% -27.78%
Inventory $6.368M $6.879M $6.527M
Prepaid Expenses
Receivables $1.900M $1.816M $1.735M
Other Receivables $0.00 $0.00 $2.609M
Total Short-Term Assets $53.90M $59.58M $88.56M
YoY Change -34.56% -32.72% 67.43%
LONG-TERM ASSETS
Property, Plant & Equipment $10.40M $10.84M $13.10M
YoY Change -16.39% -17.25% -16.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.700M $1.600M $1.800M
YoY Change -5.56% -11.11% 38.46%
Total Long-Term Assets $12.10M $12.46M $14.86M
YoY Change -15.31% -16.1% -12.86%
TOTAL ASSETS
Total Short-Term Assets $53.90M $59.58M $88.56M
Total Long-Term Assets $12.10M $12.46M $14.86M
Total Assets $66.00M $72.05M $103.4M
YoY Change -31.71% -30.33% 47.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.300M $5.200M $4.600M
YoY Change 19.44% 13.04% 21.05%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $25.50M $26.55M $26.78M
YoY Change -6.18% -0.87% 9.72%
LONG-TERM LIABILITIES
Long-Term Debt $67.70M $67.60M
YoY Change
Other Long-Term Liabilities $37.90M $39.10M $43.10M
YoY Change -9.76% -9.28% -16.8%
Total Long-Term Liabilities $105.6M $106.7M $110.2M
YoY Change -3.35% -3.23% 112.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $25.50M $26.55M $26.78M
Total Long-Term Liabilities $105.6M $106.7M $110.2M
Total Liabilities $131.1M $133.2M $137.0M
YoY Change -3.91% -2.77% 79.72%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$65.14M -$61.15M -$33.58M
YoY Change
Total Liabilities & Shareholders Equity $66.00M $72.05M $103.4M
YoY Change -31.71% -30.33% 47.86%

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$5.071M -$5.972M -$7.345M
YoY Change -17.13% -18.69% 69.98%
Depreciation, Depletion And Amortization $600.0K $616.0K $828.0K
YoY Change -25.0% -25.6% -10.97%
Cash From Operating Activities -$5.350M -$6.421M -$8.340M
YoY Change -17.94% -23.01% -13.0%
INVESTING ACTIVITIES
Capital Expenditures $230.0K $99.00K $263.0K
YoY Change 109.09% -62.36% -59.03%
Acquisitions
YoY Change
Other Investing Activities -$20.00K $50.00K
YoY Change -75.0% 6.38%
Cash From Investing Activities -$250.0K -$99.00K -$370.0K
YoY Change 25.0% -73.24% -46.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 530.0K 0.000 30.00K
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -5.350M -$6.421M -8.340M
Cash From Investing Activities -250.0K -$99.00K -370.0K
Cash From Financing Activities 530.0K 0.000 30.00K
Net Change In Cash -5.070M -$6.520M -8.680M
YoY Change -24.55% -24.88% -15.52%
FREE CASH FLOW
Cash From Operating Activities -$5.350M -$6.421M -$8.340M
Capital Expenditures $230.0K $99.00K $263.0K
Free Cash Flow -$5.580M -$6.520M -$8.603M
YoY Change -15.84% -24.21% -15.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 plx Number Of Subsidiaries
NumberOfSubsidiaries
2 item
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18913153 shares
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19380543 shares
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
93602152 shares
CY2014Q4 us-gaap Inventory Net
InventoryNet
6667000 USD
CY2015Q1 us-gaap Assets Current
AssetsCurrent
59584000 USD
CY2014Q4 us-gaap Assets Current
AssetsCurrent
65520000 USD
CY2015Q1 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
1520000 USD
CY2014Q4 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
1555000 USD
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10839000 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11282000 USD
CY2015Q1 us-gaap Deferred Costs
DeferredCosts
105000 USD
CY2014Q4 us-gaap Deferred Costs
DeferredCosts
113000 USD
CY2015Q1 us-gaap Assets
Assets
72048000 USD
CY2014Q4 us-gaap Assets
Assets
78470000 USD
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
5195000 USD
CY2014Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
3951000 USD
CY2015Q1 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
14282000 USD
CY2014Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
15496000 USD
CY2015Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
7072000 USD
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6763000 USD
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
26549000 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26210000 USD
CY2015Q1 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
67566000 USD
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47958000 USD
CY2014Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
67464000 USD
CY2015Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
36890000 USD
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
37232000 USD
CY2014Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
912000 USD
CY2015Q1 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
2197000 USD
CY2014Q4 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
2253000 USD
CY2015Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
106653000 USD
CY2014Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
107861000 USD
CY2015Q1 us-gaap Liabilities
Liabilities
133202000 USD
CY2014Q4 us-gaap Liabilities
Liabilities
134071000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54767000 USD
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
-61154000 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-55601000 USD
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
72048000 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78470000 USD
CY2015Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1816000 USD
CY2014Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1884000 USD
CY2015Q1 us-gaap Other Assets Current
OtherAssetsCurrent
2931000 USD
CY2014Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2202000 USD
CY2015Q1 us-gaap Inventory Net
InventoryNet
6879000 USD
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-5972000 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-7345000 USD
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
419000 USD
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
670000 USD
CY2015Q1 us-gaap Depreciation
Depreciation
616000 USD
CY2014Q1 us-gaap Depreciation
Depreciation
828000 USD
CY2015Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-284000 USD
CY2014Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-14000 USD
CY2015Q1 us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
-4000 USD
CY2014Q1 us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
50000 USD
CY2015Q1 plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
1000 USD
CY2014Q1 plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
1000 USD
CY2015Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
110000 USD
CY2014Q1 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
109000 USD
CY2015Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-33000 USD
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2901000 USD
CY2015Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
735000 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
744000 USD
CY2015Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
212000 USD
CY2014Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1430000 USD
CY2015Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-893000 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-450000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6421000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-8340000 USD
CY2015Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
99000 USD
CY2014Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
263000 USD
CY2014Q1 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
57000 USD
CY2014Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
50000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-99000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-370000 USD
CY2015Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
USD
CY2014Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
31000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
USD
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
31000 USD
CY2015Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-289000 USD
CY2014Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-29000 USD
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-6809000 USD
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-8708000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86398000 USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
77690000 USD
CY2015Q1 plx Increase In Liabilities For Property Plant And Equipment
IncreaseInLiabilitiesForPropertyPlantAndEquipment
194000 USD
CY2014Q1 plx Increase In Liabilities For Property Plant And Equipment
IncreaseInLiabilitiesForPropertyPlantAndEquipment
138000 USD
CY2015Q1 plx Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
USD
CY2014Q1 plx Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
12000 USD
CY2015Q1 us-gaap Interest Paid Net
InterestPaidNet
1553000 USD
CY2014Q1 us-gaap Interest Paid Net
InterestPaidNet
1527000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-26946000 USD
CY2014Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
162000 USD
CY2014Q1 plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
508000 USD
CY2014Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
43000 USD
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
-33578000 USD
CY2015Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
202000 USD
CY2015Q1 us-gaap Stock Issued During Period Shares Share Based Compensation Forfeited
StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
1667 shares
CY2015Q1 plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
217000 USD
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2015Q1 us-gaap Revenues
Revenues
4392000 USD
CY2014Q1 us-gaap Revenues
Revenues
6696000 USD
CY2015Q1 plx Other Gains Losses
OtherGainsLosses
705000 USD
CY2014Q1 plx Other Gains Losses
OtherGainsLosses
687000 USD
CY2015Q1 us-gaap Cost Of Revenue
CostOfRevenue
2400000 USD
CY2014Q1 us-gaap Cost Of Revenue
CostOfRevenue
4073000 USD
CY2015Q1 us-gaap Gross Profit
GrossProfit
2697000 USD
CY2014Q1 us-gaap Gross Profit
GrossProfit
3310000 USD
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6762000 USD
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8152000 USD
CY2015Q1 plx Grants And Reimbursements Received Or Receivable
GrantsAndReimbursementsReceivedOrReceivable
1135000 USD
CY2014Q1 plx Grants And Reimbursements Received Or Receivable
GrantsAndReimbursementsReceivedOrReceivable
2085000 USD
CY2015Q1 plx Research Development And Engineering Expense Net
ResearchDevelopmentAndEngineeringExpenseNet
5627000 USD
CY2014Q1 plx Research Development And Engineering Expense Net
ResearchDevelopmentAndEngineeringExpenseNet
6067000 USD
CY2015Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1913000 USD
CY2014Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3711000 USD
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4843000 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6468000 USD
CY2015Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
1157000 USD
CY2014Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
915000 USD
CY2015Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
28000 USD
CY2014Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
38000 USD
CY2015Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1129000 USD
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-877000 USD
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.06
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.08
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
93200739 shares
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
92686638 shares
CY2015Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1526000 USD
CY2014Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1616000 USD
CY2015Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
136000 USD
CY2014Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
132000 USD
CY2015Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
5217000 USD
CY2014Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
4919000 USD
CY2015Q1 us-gaap Inventory Write Down
InventoryWriteDown
130000 USD
CY2015Q1 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
52800000 USD
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
PROTALIX BIOTHERAPEUTICS, INC.
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001006281
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 dei Trading Symbol
TradingSymbol
PLX

Files In Submission

Name View Source Status
0001144204-15-028431-index-headers.html Edgar Link pending
0001144204-15-028431-index.html Edgar Link pending
0001144204-15-028431.txt Edgar Link pending
0001144204-15-028431-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
plx-20150331.xml Edgar Link completed
plx-20150331.xsd Edgar Link pending
plx-20150331_cal.xml Edgar Link unprocessable
plx-20150331_def.xml Edgar Link unprocessable
plx-20150331_lab.xml Edgar Link unprocessable
plx-20150331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R2.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v409288_10q.htm Edgar Link pending
v409288_ex31-1.htm Edgar Link pending
v409288_ex31-2.htm Edgar Link pending
v409288_ex32-1.htm Edgar Link pending
v409288_ex32-2.htm Edgar Link pending